GE HealthCare Lifts 2026 Profit Outlook To $4.95-$5.05 A Share As Quarterly EPS Jumps 39.1%
The medical-imaging maker raised its full-year adjusted EPS range, and the head of its Patient Care Solutions unit is leaving to become a CEO elsewhere.
GE HealthCare, the maker of medical imaging equipment, patient monitors and diagnostic imaging agents, raised its 2026 adjusted earnings outlook to $4.95 to $5.05 a share after third-quarter diluted EPS rose 39.1% to $1.36. In an 8-K filed Wednesday, it also said the chief of its Patient Care Solutions unit is leaving.
Quarter beats last year across the board
Revenue came to $5.5 billion, up 7.2%, with organic growth of 6.2% and gains in all three segments. Pharmaceutical Diagnostics grew 13.0%, Patient Care Solutions 8.5% and Advanced Imaging Solutions 6.1%.
Diluted EPS was $1.36 against $0.98 a year earlier; adjusted EPS was $1.34 against $1.07. Net income attributable to the company was $615 million versus $446 million, and the net income margin reached 11.1% from 8.7%.
The company said margin gains came from volume, price and cost productivity and a favorable year-over-year net tariff impact, partly offset by inflation. Adjusted EBIT (earnings before interest and taxes, on the company's adjusted measure) was $913 million versus $761 million, a 16.6% margin.
CEO Peter Arduini said, "We delivered strong top-line growth and margin expansion across all segments, and robust EPS growth in the third quarter."
Guidance moves up across the board
Previous 2026 adjusted EPS guidance was $4.80 to $5.00. Organic revenue growth is now expected at about 4.0%, versus a prior range of 3.0% to 4.0%, and the adjusted EBIT margin range is 15.5% to 15.7%. Free cash flow is guided to $1.6 billion or more.
Orders grew 4.0% organically, book-to-bill was 1.03 times (orders slightly above sales), and backlog stood at $23.7 billion. Free cash flow was $793 million, up $310 million, including a $55 million tariff refund.
Cash was $2.9 billion, with $3.5 billion of revolving credit available and $10.0 billion of total debt. The board declared a quarterly dividend of $0.04 a share, up 14% from the previous quarter.
A new chief for Patient Care Solutions
Jeannette Bankes, president and CEO of Patient Care Solutions, notified the company on October 22 that she will resign; her last day is November 15. The company said she is leaving for a CEO role at a publicly traded company.
Neal Sandy, now head of PCS Product Strategy and Management, takes over on November 16. The company said he brings more than 30 years of industry experience.
The unit's revenue was $793 million in the quarter, and its segment EBIT margin rose 480 basis points to 8.6%.
SOFIE deal and spending
In October the company said it plans to buy SOFIE Biosciences from Trilantic North America for $945 million in cash, with closing expected in the first half of 2027. For the first nine months it spent $2.3 billion on acquisitions and $300 million on buybacks.
Management discussed the results on an 8:30 a.m. ET call Wednesday.
Sandy's first day running Patient Care Solutions is November 16, the day after Bankes leaves.
Sources
- 8-K Filing — GE HealthCare Technologies Inc. (GEHC) — SEC EDGAR
- Exhibit release3q26earnings.htm — GE HealthCare Technologies Inc. 8-K exhibit — SEC EDGAR
- GE HealthCare Technologies (GEHC) vs. DHR and MDT: Can a $23.9B Backlog and AI Innovation Drive a Healthcare Re-Rating? — Yahoo Finance